» Articles » PMID: 23991296

C-reactive Protein Levels Are Raised in Stable Chronic Obstructive Pulmonary Disease Patients Independent of Smoking Behavior and Biomass Exposure

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2013 Aug 31
PMID 23991296
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this case control study is to assess the relationship between serum C-reactive protein (CRP) levels and well-known clinical parameters in Chronic obstructive pulmonary disease (COPD) considering the impact of smoking behavior, biomass exposure and accompanying clinical entities, namely pulmonary hypertension, systemic hypertension and diabetes mellitus.

Methods: Spirometry, echocardiography, arterial oxygen saturation (SpO2) measurements, BODE scores and serum CRP levels were investigated in stable COPD patients. Associations between CRP levels and clinical parameters were evaluated.

Results: CRP levels are significantly higher in COPD patients than in healthy controls. CRP levels were not significantly different between COPD patients treated with inhaled corticosteroids and those not treated. CRP levels significantly correlated with age, FEV1% predicted, FVC% predicted, SpO2, MMRC, 6 minute walk distance, BODE scores and haemoglobin levels. In multivariate analysis BODE scores and concomitant systemic hypertension manifested the strongest association with CRP levels. CRP levels in COPD patients with and without pulmonary hypertension were significantly different. CRP levels did not differ significantly according to smoking status or biomass exposure, moreover COPD cases due to biomass exposure who never smoked also had higher CRP levels compared to healthy controls.

Conclusions: Systemic inflammation is inherent to COPD independent of ever-smoking status and correlates with disease severity, concomitant systemic hypertension and pulmonary hypertension.

Citing Articles

Advancements in Breathomics: Special Focus on Electrochemical Sensing and AI for Chronic Disease Diagnosis and Monitoring.

Subawickrama Mallika Widanaarachchige N, Paul A, Banga I, Bhide A, Muthukumar S, Prasad S ACS Omega. 2025; 10(5):4187-4196.

PMID: 39959047 PMC: 11822511. DOI: 10.1021/acsomega.4c10008.


Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.

Tran A, Ghanem A, More M, Nagy A, Toth A Antibiotics (Basel). 2025; 13(12.

PMID: 39766500 PMC: 11672715. DOI: 10.3390/antibiotics13121110.


Elevated inflammatory burden index increases mortality in adults with chronic inflammatory airway diseases: a nationwide cohort study.

Zhu N, Lin S, Wang L, Kong X, Huang W, Cao C BMC Pulm Med. 2024; 24(1):399.

PMID: 39164650 PMC: 11337749. DOI: 10.1186/s12890-024-03211-6.


Evaluation of Salivary Biomarkers and Spirometry for Diagnosing COPD in Non-Smokers and Smokers of Polish Origin.

Rudzinska-Radecka M, Bancerowski B, Marczynski R, Mukherjee D, Sikora T, Morawska K Biomedicines. 2024; 12(6).

PMID: 38927413 PMC: 11200520. DOI: 10.3390/biomedicines12061206.


Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity.

Dimiene I, Hoppenot D, Vajauskas D, Padervinskiene L, Rimkunas A, Zemaitis M J Clin Med. 2024; 13(10).

PMID: 38792478 PMC: 11121926. DOI: 10.3390/jcm13102937.


References
1.
Man S, Connett J, Anthonisen N, Wise R, Tashkin D, Sin D . C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61(10):849-53. PMC: 2104755. DOI: 10.1136/thx.2006.059808. View

2.
Lopez-Campos J, Arellano E, Calero C, Delgado A, Marquez E, Cejudo P . Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol. 2012; 12:40. PMC: 3340310. DOI: 10.1186/1471-2288-12-40. View

3.
Virdis A, Ghiadoni L, Plantinga Y, Taddei S, Salvetti A . C-reactive protein and hypertension: is there a causal relationship?. Curr Pharm Des. 2007; 13(16):1693-8. DOI: 10.2174/138161207780831365. View

4.
Sin D, Paul Man S . Is systemic inflammation responsible for pulmonary hypertension in COPD?. Chest. 2006; 130(2):310-2. DOI: 10.1378/chest.130.2.310. View

5.
Joppa P, Petrasova D, Stancak B, Tkacova R . Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006; 130(2):326-33. DOI: 10.1378/chest.130.2.326. View